Cardio-facio-cutaneous syndrome (CFCS) belongs to RASopathies, a group of conditions caused by mutations in genes encoding proteins of the rat sarcoma/mitogen-activated protein kinase (RAS/MAPK) pathway. It is a rare syndrome, with about 300 patients reported. Main clinical manifestations include facial dysmorphisms, growth failure, heart defects, developmental delay, and ectodermal abnormalities. Mutations (mainly missense) of four genes (BRAF, MAP 2 K1, MAP 2 K2, and KRAS) have been associated to CFCS. However, whole gene deletions/duplications and chromosomal microdeletions have been also reported. Specifically, 19p13.3 deletion including MAP 2 K2 gene are responsible for cardio-facio-cutaneous microdeletion syndrome, whose affected subjects show more severe phenotype than CFCS general population.
Hereby, we report on a female newborn with prenatal diagnosis of omphalocele, leading to further genetic investigations through amniocentesis. Among these, array comparative genomic hybridization (a-CGH) identified a 19p13.3 microdeletion, spanning 1.27 Mb and including MAP 2 K2 gene. Clinical features at birth (coarse face with dysmorphic features, sparse and friable hair, cutaneous vascular malformations and hyperkeratotic lesions, interventricular septal defect, and omphalocele) were compatible with CFCS diagnosis, and further postnatal genetic investigations were not considered necessary. Soon after discharge, at around 1 month of life, she was readmitted to our Neonatal Intensive Care Unit due to repeated episodes of vomiting, subtending a hypertrophic pyloric stenosis (HPS) which was promptly identified and treated.
Our report supports the 19p13.3 microdeletion as a contiguous gene syndrome, in which the involvement of the genes contiguous to MAP 2 K2 may modify the patients’ phenotype. It highlights how CFCS affected subjects, including those with 19p13.3 deletions, may have associated gastrointestinal defects (e.g., omphalocele and HPS), providing further data on 19p13.3 microdeletion syndrome, and a better characterization of its genomic and phenotypic features. The complex clinical picture of such patients may be worsened by additional, and even precocious, life-threatening conditions like HPS. Clinicians must consider, anticipate and/or promptly treat possible medical and surgical complications, with the aim of reducing adverse outcomes. Extensive diagnostic work-up, and early, continuous, and multidisciplinary follow-up, as well as integrated care, are necessary for the longitudinal clinical evolution of any single patient.
Cardio-facio-cutaneous syndrome (CFCS) belongs to RASopathies, a group of conditions caused by germline mutations in genes encoding components or regulators of the rat sarcoma/mitogen-activated protein kinase (RAS/MAPK) pathway , main mechanism regulating cell growth and differentiation, proliferation, migration, and apoptosis . It is a rare condition, with about 300 reported patients. Main clinical manifestations include facial dysmorphisms, growth failure, heart defects, developmental delay including intellectual disability, and ectodermal abnormalities (sparse and friable hair, hyperkeratotic and/or generalized ichthyosis-like lesions). Mutations of four genes have been associated to CFCS: BRAF (7q34), MAP 2 K1 (15q22.31), MAP 2 K2 (19p13.3, Cardio-facio-cutaneous syndrome 4, OMIM #615280), and KRAS (12p12.1). They encode for the RAS protein (KRAS) and/or its downstream signaling serine-threonine kinases (BRAF, MEK1, MEK2). Most of them are missense variants. However, whole gene deletions or duplications and chromosomal microdeletions have been also reported. Chromosome region 19p13.3 harbors MAP 2 K2 gene. Deletions of such genomic band including this gene are associated to cardio-facio-cutaneous microdeletion syndrome, whose affected subjects show more severe phenotype than CFCS general population.
Hereby, we report on a female newborn with prenatal diagnosis of omphalocele, leading to further genetic investigations through amniocentesis. Among these, array comparative genomic hybridization (CGH) identified a 19p13.3 deletion, including MAP 2 K2 gene. Clinical features at birth were compatible with CFCS diagnosis, and further postnatal genetic investigations were not considered necessary. Soon after discharge, at around 1 month of life, she was readmitted to our Neonatal Intensive Care Unit (NICU), due to repeated episodes of vomiting. A hypertrophic pyloric stenosis was, then, also found and promptly treated.
A female newborn was the first child of healthy and nonconsanguineous parents. Family history was unremarkable. Pregnancy was marked by gestational diabetes, treated with insulin. The first prenatal ultrasound (US), performed at 14 weeks of gestation (WG), disclosed omphalocele. Then, further genetic investigations through amniocentesis were recommended and performed. Karyotype analysis showed a normal female chromosomal set, and molecular analysis of 11p15 genomic region did not disclose abnormalities. Conversely, a-CGH (100–150 Kb resolution, genome assembly GRCh37.p13) identified a 19p13.3 deletion. The genomic rearrangement of 1.27 Mb spanned from position 2,980,128 to 4,251,077, and included, besides MAP 2 K2, further genes: TLE6, GNA11, GIPC3, TBXA2R, PIP5K1C, RAX2, ATCAY, EEF2 and CREB3L3 (Fig. 1). The following prenatal US evaluations documented increased head circumference (+ 2 standard deviation, SD) in addition to polyhydramnios, but ruled out other major malformations. A female newborn was delivered at 38 WG by caesarean section. At birth, anthropometric measurements were as follows: weight 4040 g (>99th centile, + 2.82 SD), length 50 cm (81st centile, + 0.88 SD), and occipitofrontal circumference (OFC) 36 cm (99th centile, + 2.23 SD). Apgar scores were 7, 8, and 9 at 1, 5 and 10 min respectively. Postnatally, due to respiratory distress which needed non-invasive ventilatory support (continuous positive airway pressure administration), she was transferred to our NICU. At admission, physical examination showed macrocephaly, high and prominent forehead, hypoplastic supraorbital ridges, facial asymmetry due to left hypoplasia, coarse face, sparse and friable hair, eyebrows, and eyelashes, left palpebral ptosis, down slanting palpebral fissures, wide and depressed nasal bridge, bulbous tip, anteverted nares, long philtrum and macroglossia. Bilateral small, dysplastic, crumbled and posteriorly rotated ears, with thickened helices and right preauricular tag completed her craniofacial profile (Fig. 2a/b). Wide cutaneous vascular malformations posteriorly in the neck and occiput, hyperkeratotic lesions in the right eyebrow skin region, bilateral adducted thumb, syndactyly of the right 2nd and 3rd toes, broad 1st, proximal set of the 4th and clinodactyly of the 5th ones, as well as omphalocele were also observed (Fig. 3a/b/c). Mild generalized hypotonia, in addition to poor reactivity, spontaneous motor activity and suction outlined her neurological profile. Laboratory examinations, including complete blood count, serum electrolytes, liver and kidney function tests, showed normal results. Head US revealed hypoplasia of cerebellum and body and splenium of the corpus callosum, as well as increased size of the lateral ventricles. Heart US identified two mid-apical muscular interventricular septal defects, in addition to mild supravalvular aortic dilation, bovine aortic arch, and patent foramen ovale. Ophthalmological evaluation, and hearing screening through transient evoked otoacoustic emissions (TEOAEs), revealed no abnormalities.
In the second day of life, our baby underwent surgery to repair omphalocele. The following postoperative clinical evolution was characterized by initial feeding difficulties, which required nasogastric tube support, and subsequent gradual recovery with achievement of optimal exclusive breastfeeding at around 2 weeks of life. In the meantime, she briefly (for about 24 h after the surgical correction) needed invasive mechanical ventilation, and then exclusively oxygen support until the third week of life. Then, the clinical course occurred without complications, and she was discharged in good general conditions and adequate weight and length growth at age 1 month. After 6 days, the baby presented with recurrent vomiting. Thus, she was readmitted to our NICU, where an abdominal US was soon carried out. This showed pyloric muscle thickness (MT) of 4–5 mm, and channel length (CL) 18 mm, according with a hypertrophic pyloric stenosis (HPS) diagnosis. She then begun intravenous rehydration and whole parenteral nutrition, and underwent Ramstedt pyloromyotomy 3 days later. Feeding through nasogastric tube was started on day 3 after surgery, and enteral nutrition was gradually increased. The patient was discharged 1 week after the surgical operation, tolerating full oral feeding. She had a normal clinical evolution, with adequate weight gain, and is included in a multidisciplinary follow-up. She currently is 2 months and 24 days old, and her anthropometric measures, according to World Health Organization growth chart for neonatal and infant close monitoring , are: weight 4960 g (14th centile, − 1.10 SD), length 58 cm (27th centile, -0.60 SD) and OFC 39 cm (41th centile, − 0.22 SD). She shows mild developmental delay, with axial central type hypotonia, normal tone of the limbs and archaic and osteotendinous reflexes. She has no other clinical and/or instrumental abnormalities, except for a plane vascular malformation in the dorsal region (maximum diameters 0.7 × 0.5 cm).
Discussion and conclusions
Cardio-facio-cutaneous syndrome (CFCS) is a congenital disorder characterized by distinctive craniofacial features, heart defects (CHD, including pulmonic stenosis, atrial septal defect, and hypertrophic cardiomyopathy), developmental delay/intellectual disability, and ectodermal abnormalities (sparse and friable hair, hyperkeratotic skin lesions, generalized ichthyosis-like conditions). Typical facial dysmorphisms are high forehead with bitemporal narrowing, hypoplastic supraorbital ridges, down slanting palpebral fissures, depressed nasal bridge, and posteriorly angulated ears with prominent helices . Craniofacial features are like those observed in Noonan syndrome. However, CFCS patients usually have more severe medical complications and developmental delay/intellectual disability . Then, CFCS clinical features overlap with those of Noonan and Costello syndromes, but skin involvement is specific for CFCS, allowing to distinguish it from other RASopathies. Indeed, all CFCS patients develop some form of cutaneous lesions and, therefore, dermatological consultation and follow-up are recommended. Specifically, infantile hemangiomas are seen in 25% of cases (higher than other RASopathies)  and were observed also in the present patient.
Chromosome 19 has the highest gene density within human DNA. However, deletions and duplications of the 19p13.3 terminal band are poorly reported . The microdeletion found in our patient partially matches other deletions, within the same region, previously described in patients showing variable CFCS phenotype (mostly overlapping to that of the proband). This further supports the evidence of a recognizable clinical picture [9, 10], although in none of the reported affected subjects’ gastrointestinal defects, like those seen in our patient, were observed . Gastrointestinal anomalies have been frequently observed in CFCS patients , but omphalocele and HPS are scarcely documented.
Activating gain-of-function missense mutations of MAP 2 K2 are mostly responsible for CFCS. However, although rarely reported, the syndrome is also associated to MAP 2 K2 haploinsufficiency, or to 19p13.3 microdeletion including such gene. The 1.27 Mb rearrangement identified in our patient contains, besides MAP 2 K2, about thirty further genes, and nine of them are known to be disease causing (TLE6, GNA11, GIPC3, TBXA2R, PIP5K1C, RAX2, ATCAY, EEF2 and CREB3L3) (Fig. 3). GIPC3 encodes for a protein, highly expressed in the spinal ganglion and inner ear sensitive hairy cells. Its mutations cause an autosomal recessive form of non-syndromic sensorineural deafness . It has, moreover, a high expression in small intestine and jejunum, and then its deletions may contribute to the gastrointestinal defects observed in our patient. TBXA2R mutations are associated to platelet-related bleeding . PIP5K1C mutations cause autosomal recessive lethal congenital contractural syndrome type 3 . RAX2 is expressed in the retina, and its mutations are associated to macular degeneration and cone rod dystrophy . ATCAY mutations may cause autosomal recessive Cayman cerebellar ataxia, while those of EEF2 (MIM #130610) spinocerebellar ataxia . Finally, heterozygous variants of CREB3L3 (MIM #661998) are associated to hypertriglyceridemia . Our patient shows cerebellar hypoplasia and mild developmental delay, but no hematological (platelet alterations), metabolic (lipidic profile), and ocular abnormalities, although the appearance of such anomalies over time cannot be ruled out. The other genes in the deleted region may also play a causative role for the phenotype, but it is hard to establish their involvement as well as genotype-phenotype correlations [19, 20]. However, our results support the evidence of 19p13.3 microdeletion as contiguous gene syndrome, in which some of the genes contiguous to MAP 2 K2 may modify patients’ phenotype (e.g. GIPC3 associated to gastrointestinal defects) [21, 22].
Our report highlights how CFCS patients, including those with 19p13.3 deletions, may have associated gastrointestinal defects (e.g. omphalocele and HPS). It provides further data on 19p13.3 microdeletion syndrome expanding the phenotype, in view of a better characterization of its genomic and clinical features. More patients with overlapping deletions are needed to support our findings, and to define the contribution of the involved genes.
Extensive diagnostic work-up, as well as early, continuous, long-term and multidisciplinary follow-up  (oncologic for increased risk of acute lymphoblastic leukemia, non-Hodgkin lymphoma, Langerhans cell histiocytosis, and hepatoblastoma [24, 25]; cardiologic; neurodevelopmental; dermatological, also for vascular malformations and angiomas; ophthalmological/audiological, and surgical/gastroenterological for risk of HPS, umbilical hernia, anal atresia and other malformations) and integrated care, are necessary for these patients. Their complex clinical phenotype may be worsened by additional, and even early, life-threatening conditions like HPS, as occurred in the present patient [26, 27]. Clinicians must consider and promptly treat the possible medical and surgical complications, with the aim of reducing the adverse outcomes according to an individualized approach.
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Array comparative genomic hybridization
Congenital heart defect
Fluorescence in situ hybridization
Hypertrophic pyloric stenosis
Neonatal intensive care unit
Transient evoked otoacoustic emissions
Weeks of gestation
Gos M, Smigiel R, Kaczan T, Landowska A, Abramowicz A, Sasiadek M, et al. MAP 2K2 mutation as a cause of cardio-facio-cutaneous syndrome in an infant with a severe and fatal course of the disease. Am J Med Genet A. 2018;176(7):1670–4.
Bezniakow N, Gos M, Obersztyn E. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes. Dev Period Med. 2014;18(3):285–96.
Al-Kateb H, Hahn A, Gastier-Foster JM, Jeng L, McCandless SE, Curtis CA. Molecular characterization of a novel, de novo, cryptic interstitial deletion on 19p13.3 in a child with a cutis aplasia and multiple congenital anomalies. Am J Med Genet A. 2010;152A(12):3148–53.
de Smith AJ, van Haelst MM, Ellis RJ, Holder SE, Payne SJ, Hashim SK, et al. Chromosome 19p13.3 deletion in a patient with macrocephaly, obesity, mental retardation, and behavior problems. Am J Med Genet A. 2011 May;155A(5):1192–5.
Krauss M, Kukhtina V, Pechstein A, Haucke V. Stimulation of phosphatidylinositol kinase type I-mediated phosphatidylinositol (4,5)-bisphosphate synthesis by AP-2 mu-cargo complexes. Proc Natl Acad Sci. 2006;103:11934–9.
Nardello R, Plicato G, Mangano GD, Gennaro E, Mangano S, Brighina F, et al. Two distinct phenotypes, hemiplegic migraine and episodic Ataxia type 2, caused by a novel common CACNA1A variant. BMC Neurol. 2020;20(1):155.
Corsello G, Antona V, Serra G, Zara F, Giambrone C, Lagalla L, et al. Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1. Ital J Pediatr. 2018;44(1):45.
Uludağ Alkaya D, Lissewski C, Yeşil G, Zenker M, Tüysüz B. Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1. Am J Med Genet A. 2021;185(12):3623–33.
Harms FL, Alawi M, Amor DJ, Tan TY, Cuturilo G, Lissewski C, et al. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor. Am J Med Genet A. 2018 Feb;176(2):470–6.
Pride HB, Tollefson M, Silverman R. What's new in pediatric dermatology?: part I. diagnosis and pathogenesis. J Am Acad Dermatol 2013;68(6):885.e1–898.
Serra G, Memo L, Coscia A, Giuffré M, Iuculano A, Lanna M, et al. Their respective scientific societies and parents’ associations. Recommendations for neonatologists and pediatricians working in first level birthing centers on the first communication of genetic disease and malformation syndrome diagnosis: consensus issued by 6 Italian scientific societies and 4 parents' associations. Ital. J Pediatr. 2021;47(1):94.
GC and GS conceptualized the report. SF collected clinical and genetical data, and drafted the first version of the manuscript. GS wrote the final version of the manuscript and took care of the patient. VA contributed to the acquisition and interpretation of genetical data. MRDP performed surgical assessment, operations and follow-up. MG contributed in drafting the manuscript and took care of the patient. EP performed neurological and developmental assessment. GC revised the manuscript and gave final approval of the version to be submitted. All authors approved the final manuscript as submitted.
Written informed consent was obtained from parents at admission of their newborn. The study was approved by the Mother and Child Department of the University of Palermo (Palermo, Italy). All procedures performed in this report were in accordance with the ethical standards of the institutional and national research committee, and with the 1964 Helsinki declaration and its later amendments, or comparable ethical standards.
Consent for publication
Written informed consent for publication was obtained.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Serra, G., Felice, S., Antona, V. et al. Cardio-facio-cutaneous syndrome and gastrointestinal defects: report on a newborn with 19p13.3 deletion including the MAP 2 K2 gene.
Ital J Pediatr48, 65 (2022). https://doi.org/10.1186/s13052-022-01241-6